Preliminary analysis of short-term real-world outcomes of telitacicept in high-risk IgA nephropathy
Our preliminary real-world findings suggest that telitacicept may be a safe and effective treatment for high-risk IgAN patients, significantly reducing proteinuria and preserving renal function. Its therapeutic benefits were more pronounced when used as initial therapy.
Authors
- Xinfang Xie (ORCID: https://orcid.org/0000-0002-0872-2986)
- Ping Lan (ORCID: https://orcid.org/0000-0002-8901-8498)
- YingLiang Ma (ORCID: https://orcid.org/0000-0001-5770-5843)
- Wanhong Lu
- SUN Jiping
- Huixian Li (ORCID: https://orcid.org/0000-0002-3713-8017)
- Xiaoyan Yu (ORCID: https://orcid.org/0000-0003-0351-8393)
- Jing Han (ORCID: https://orcid.org/0009-0000-5815-334X)
Institutions
- Northwest University (CN)
- First Affiliated Hospital of Xi'an Jiaotong University (CN)
- Shaanxi Provincial Hospital of Traditional Chinese Medicine (CN)
Publication Details
- Journal
- Frontiers in Medicine
- Published
- 2025-12-05
- DOI
- https://doi.org/10.3389/fmed.2025.1698028
- Primary Topic
- Renal Diseases and Glomerulopathies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Natural Science Foundation of Shaanxi Province